Dr. Steven Dyson is a Partner in the Healthcare team and is based in London. He joined Apax Partners in 2000 and has both led and participated in a number of key deals including Rodenstock, Candela, Unilabs, Vyaire Medical, Neuraxpharm, Acelity (formerly KCI), GENEX, Capio, and Zeneus Pharma.
Prior to joining Apax Partners, Steven was a consultant with McKinsey & Company.
Steven holds a BA in Biochemistry from Oxford University and a PhD in Developmental Biology from Cambridge University.
Steven serves as a director and board member to Rodenstock, Healthium MedTech, Candela, Unilabs and Vyaire Medical. He previously served on the boards of Acelity, Capio and Genex.
Steven joined Apax at the turn of the Millennium, drawn by the Firm’s sector specialisation, which enabled him to pursue his passion for healthcare and the opportunity to work with the most talented management teams. He continues to be inspired by the opportunity to back companies bringing life-changing products and services to patients, whilst creating value for all stakeholders.